Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

284 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS]).
Aakash F, Gisriel SD, Zeidan AM, Bennett JM, Bejar R, Bewersdorf JP, Borate UM, Boultwood J, Brunner AM, Buckstein R, Carraway HE, Churpek JE, Daver NG, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Garcia-Manero G, Gore SD, Greenberg PL, Griffiths EA, Halene S, Hourigan CS, Kim TK, Kim N, Komrokji RS, Kutchroo VK, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Platzbecker U, Della Porta MG, Roboz GJ, Sallman DA, Santini V, Sanz G, Savona MR, Sekeres MA, Stahl M, Starczynowski DT, Steensma DP, Taylor J, Abdel-Wahab O, Wei AH, Xie Z, Xu ML, Hasserjian RP, Loghavi S. Aakash F, et al. Among authors: efficace f. Mod Pathol. 2024 Dec;37(12):100615. doi: 10.1016/j.modpat.2024.100615. Epub 2024 Sep 23. Mod Pathol. 2024. PMID: 39322118 Review.
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes.
Komrokji RS, Lanino L, Ball S, Bewersdorf JP, Marchetti M, Maggioni G, Travaglino E, Al Ali NH, Fenaux P, Platzbecker U, Santini V, Diez-Campelo M, Singh A, Jain AG, Aguirre LE, Tinsley-Vance SM, Schwabkey ZI, Chan O, Xie Z, Brunner AM, Kuykendall AT, Bennett JM, Buckstein R, Bejar R, Carraway HE, DeZern AE, Griffiths EA, Halene S, Hasserjian RP, Lancet J, List AF, Loghavi S, Odenike O, Padron E, Patnaik MM, Roboz GJ, Stahl M, Sekeres MA, Steensma DP, Savona MR, Taylor J, Xu ML, Sweet K, Sallman DA, Nimer SD, Hourigan CS, Wei AH, Sauta E, D'Amico S, Asti G, Castellani G, Delleani M, Campagna A, Borate UM, Sanz G, Efficace F, Gore SD, Kim TK, Daver N, Garcia-Manero G, Rozman M, Orfao A, Wang SA, Foucar MK, Germing U, Haferlach T, Scheinberg P, Miyazaki Y, Iastrebner M, Kulasekararaj A, Cluzeau T, Kordasti S, van de Loosdrecht AA, Ades L, Zeidan AM, Della Porta MG; International Consortium on Myelodysplastic Syndromes. Komrokji RS, et al. Among authors: efficace f. Lancet Haematol. 2024 Nov;11(11):e862-e872. doi: 10.1016/S2352-3026(24)00251-5. Epub 2024 Oct 9. Lancet Haematol. 2024. PMID: 39393368 Review.
Health-related quality of life outcomes in randomized controlled trials in metastatic hormone-sensitive prostate cancer: a systematic review.
Osanto S, Vliert-Bout AV, Gomez de Segura CA, Efficace F, Sparano F, Willemse PP, Schoones J, Cohen A, Barjesteh van Waalwijk van Doorn-Khosrovani S. Osanto S, et al. Among authors: efficace f. EClinicalMedicine. 2024 Nov 13;78:102914. doi: 10.1016/j.eclinm.2024.102914. eCollection 2024 Dec. EClinicalMedicine. 2024. PMID: 39619239 Free PMC article. Review.
Health-related quality of life benefits of arsenic trioxide in patients with non-high-risk acute promyelocytic leukemia are sustained over time: long-term results of the GIMEMA APL0406 trial.
Efficace F, Sparano F, Breccia M, Greco C, Carluccio P, Borlenghi E, Salutari P, Levato L, Baldi T, Mancini V, Finizio O, Autore F, Fazi P, Platzbecker U, Vignetti M, Voso MT. Efficace F, et al. Ann Hematol. 2024 Oct 23. doi: 10.1007/s00277-024-06038-7. Online ahead of print. Ann Hematol. 2024. PMID: 39438322
Response to Dr. Ying Cui comments.
Mulas O, Efficace F, Costa A, Baldi T, Zerbini F, Mantovani D, Morelli E, Perra D, La Nasa G, Caocci G. Mulas O, et al. Among authors: efficace f. Ann Hematol. 2024 Sep;103(9):3829. doi: 10.1007/s00277-024-05914-6. Epub 2024 Jul 30. Ann Hematol. 2024. PMID: 39078436 No abstract available.
Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohort.
Anota A, Basset M, Charton E, Bommier C, Efficace F, Dupuis J, Cottone F, Bouabdallah KK, Mollevi C, Ysebaert L, Winter A, Bijou F, Préau M, Chauchet A, Bernier A, Fornecker LM, Hafirassou H, Carras S, Lachenal F, Lionne-Huyghe P, Detourmignies L, Leyronnas C, Drénou B, Peyrou SLG, Abraham J, Monnereau A, Fouillet L, Morschhauser F, Rossi C, Belot A, Ghesquières H. Anota A, et al. Among authors: efficace f. Eur J Cancer. 2024 Sep;208:114210. doi: 10.1016/j.ejca.2024.114210. Epub 2024 Jul 4. Eur J Cancer. 2024. PMID: 39002346
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial.
Efficace F, Mahon FX, Richter J, Piciocchi A, Cipriani M, Nicolini FE, Mayer J, Zackova D, Janssen JJWM, Panayiotidis P, Vestergaard H, Koskenvesa P, Almeida A, Hjorth-Hansen H, Martinez-Lopez J, Olsson-Strömberg U, Hochhaus A, Berger MG, Etienne G, Klamova H, Faber E, Rousselot P, Pfirrmann M, Saussele S. Efficace F, et al. Leukemia. 2024 Aug;38(8):1722-1730. doi: 10.1038/s41375-024-02341-4. Epub 2024 Jul 10. Leukemia. 2024. PMID: 38987274
284 results